Abstract
The first influenza pandemic in over 40 years was caused by a novel influenza A strain, A(H1N1)pdm09. Fortunately, most of those infected suffered mild disease. However, a significant minority of young adults and children exhibited severe illness, sometimes resulting in respiratory failure and even death. In the UK, A(H1N1)pdm09 influenza also caused a large disease burden the post-pandemic winter of 2010/11, stretching some healthcare resources to the limit. Although some pre-existing conditions increased the risk of severe disease, pregnant women and those with no underlying health problems contributed substantially to the total number of hospitalisations. Why outcomes of infection vary so widely is unknown and optimal personalised treatment strategies are yet to be developed. In this review, we give an overview of A(H1N1)pdm09 influenza in adults and the evidence supporting pharmacological interventions, with a focus on the use of antiviral agents.
Keywords: Antiviral, H1N1, influenza, pandemic, treatment, respiratory failure, vaccination, Dyspnoea, chronic obstructive pulmonary disease
Current Respiratory Medicine Reviews
Title:Severe Influenza: Clinical Features and Treatment Options
Volume: 8 Issue: 3
Author(s): Jake Dunning and Peter Openshaw
Affiliation:
Keywords: Antiviral, H1N1, influenza, pandemic, treatment, respiratory failure, vaccination, Dyspnoea, chronic obstructive pulmonary disease
Abstract: The first influenza pandemic in over 40 years was caused by a novel influenza A strain, A(H1N1)pdm09. Fortunately, most of those infected suffered mild disease. However, a significant minority of young adults and children exhibited severe illness, sometimes resulting in respiratory failure and even death. In the UK, A(H1N1)pdm09 influenza also caused a large disease burden the post-pandemic winter of 2010/11, stretching some healthcare resources to the limit. Although some pre-existing conditions increased the risk of severe disease, pregnant women and those with no underlying health problems contributed substantially to the total number of hospitalisations. Why outcomes of infection vary so widely is unknown and optimal personalised treatment strategies are yet to be developed. In this review, we give an overview of A(H1N1)pdm09 influenza in adults and the evidence supporting pharmacological interventions, with a focus on the use of antiviral agents.
Export Options
About this article
Cite this article as:
Dunning Jake and Openshaw Peter, Severe Influenza: Clinical Features and Treatment Options, Current Respiratory Medicine Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339812800493223
DOI https://dx.doi.org/10.2174/157339812800493223 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Soluble Adhesion Molecules in the Pathogenesis of Rheumatoid Arthritis
Current Pharmaceutical Design Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Proinflammatory Activities of Leptin in Non-Autoimmune Conditions
Inflammation & Allergy - Drug Targets (Discontinued) Gastroenterological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Recent Clinical Evidence for the Treatment of Osteoarthritis: What we have Learned
Reviews on Recent Clinical Trials Editorial (Thematic Issue: The Thoracic Space: An Amazing Pandora’s Box!)
Current Respiratory Medicine Reviews Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis: An Uncommon Yet Important Complication
Current Rheumatology Reviews Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Transgenic Models in Allergic Responses
Current Drug Targets Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Current Respiratory Medicine Reviews Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Systemic Inflammation Induces Endothelial Dysfunction in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued)